Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Rhea-AI Summary

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live webcast to discuss its first quarter 2025 financial results on Monday, May 12, 2025, at 4:30 p.m. ET.

The company, which maintains a pipeline of seven brain disease programs including two clinical-stage programs, will also provide a business update during the call. Interested participants can access the webcast through the events and presentations section of Neumora's website, with a replay available for up to 30 days after the event.

News Market Reaction

+0.67%

1 alert

+0.67% News Effect

On the day this news was published, NMRA gained 0.67%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update.

A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com

FAQ

When will Neumora Therapeutics (NMRA) release Q1 2025 earnings?

Neumora Therapeutics will release Q1 2025 earnings on Monday, May 12, 2025, at 4:30 p.m. ET via conference call and webcast.

How many drug development programs does Neumora Therapeutics (NMRA) currently have?

Neumora Therapeutics currently has seven brain disease programs in its pipeline, including two that are in clinical-stage development.

How can investors access Neumora's (NMRA) Q1 2025 earnings call?

Investors can access the earnings call by registering for the conference call or viewing the live webcast through the events section of Neumora's website at www.neumoratx.com.

How long will Neumora's (NMRA) Q1 2025 earnings webcast replay be available?

The webcast replay will be archived and available for up to 30 days following the completion of the event.